Mylan

Credit Line and Bonds: Teva's Financial Catch

12.08.19 | Uri Tal-Tene

Copaxone-Competitor Developer Mapi Pharma Gets Funding for Jerusalem Plant

19.03.19 | Lilach Baumer

Teva, Mylan Drop on Announcement of Epinephrine Injector Rival

09.12.18 | Lilach Baumer

Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says

26.08.18 | Dror Reich

Teva Wins FDA Approval for First Generic EpiPen

19.08.18 | Lilach Baumer

Court Rules Allergan Can't Use Indian Tribe Deal to Protect Patents

23.07.18 | CTech

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18 | Lilach Baumer

CTech’s Daily Israeli Tech News Roundup

17.12.17 | CTech

Teva Wants to Be Like Mylan: Agile, Lean and Profitable

17.12.17 | Uri Tal-Tenne

CTech’s Daily Israeli Tech News Roundup

26.11.17 | CTech

Mylan's Chairman was Right

26.11.17 | Sophie Shulman

Investors Cheer as Mylan Plans to Delist from Israeli Stock Exchange

12.11.17 | Uri Tal-Tenne and Dror Reich

With New CEO in Seat, Teva Lowers Outlook

02.11.17 | Lilach Baumer and Dror Reich

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17 | Lilach Baumer

Teva Loses Copaxone Market Exclusivity

04.10.17 | Lilach Baumer

U.S. Congress to Investigate Rising Multiple Sclerosis Drug Prices

21.08.17 | Dror Reich

With Bloated Debt, Teva Looks to Sell Assets

10.08.17 | Eli Shimony and Gil Kalian